ARWR
ARROWHEAD PHARMACEUTICALS, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 5 ▼ 1 insider sell $641.9K at $64.19
- Mar 30 Trial readout: T-90d Trial Readout: Plozasiran Injection (Phase 3)
- Apr 1 Trial readout: T-90d Trial Readout: Plozasiran Injection (Phase 3)
- Apr 2 Trial readout: T-60d Trial Readout: Plozasiran Injection (Phase 3)
- Apr 22 to Apr 23 ▼ 2 days of insider sells: $1.7M by 2 insiders, avg $72.93
- May 12 ▼ 1 insider sell $228.3K at $76.88
- Jul 14 Stifel initiates
- Aug 18 ▼ 2 insiders sell $1.2M at $87.25
- Sep 8 Citigroup initiates
- Nov 12 ▼ Arrowhead Pharmaceuticals reported fiscal 2026 full-year revenue of…
- Nov 12 ▼ Earnings: ARWR Q4 2026 Earnings: EPS $-3.04 (-87.8% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
5 insiders sold $3.7M.
- InstitutionsMIXED
Q3 2026: 28 added (1 new), 30 trimmed or exited.
- AnalystsBULLISH
20 of 21 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest +5.7% to 11.58M shares. 8.5 days to cover, ≈8.2% of shares.
- TrendDOWNTREND
29% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MORGAN STANLEY | ADD | $120.1M |
| Pictet Asset Management Holding SA | ADD | $50.2M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $47.9M |
| FIRST TRUST ADVISORS LP | TRIM | $28.9M |
| Connor, Clark & Lunn Investment Management Ltd. | TRIM | $28.6M |
| Aberdeen Group plc | ADD | $27.0M |
| PRINCIPAL FINANCIAL GROUP INC | TRIM | $24.0M |
| JANE STREET GROUP, LLC | ADD | $23.8M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
21 analystsPrice is below the lowest target. Median implies +139%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 13, 2026 | RBC Capital REITERATE | Outperform |
| Nov 13, 2026 | Stifel MAINTAIN | Buy |
| Oct 15, 2026 | Chardan Capital MAINTAIN | Buy |
| Oct 15, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Sep 8, 2026 | Citigroup INITIATE | Buy |
| Sep 1, 2026 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
OLUKOTUN ADEOYE Y Director Aug 18, 2026 | SELL | $173.9K |
PERRY MICHAEL S Director Aug 18, 2026 | SELL | $1.0M |
Cohen Matthew Gregory Director Jun 15, 2026 | AWARD | 11,882 sh |
Lu Hongbo Director May 12, 2026 | SELL | $228.3K |
Hamilton James C Chief Medical Officer Apr 23, 2026 | SELL | $750.0K |
Apel Daniel Joseph Chief Financial Officer Apr 22, 2026 | SELL | $224.9K |
Apel Daniel Joseph Chief Financial Officer Apr 22, 2026 | SELL | $627.9K |
Apel Daniel Joseph Chief Financial Officer Apr 22, 2026 | SELL | $81.5K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
7 filings · 1 bullish · 2 bearish · 1 mixed · 3 neutral- BEARISH 8-KNov 12, 2026
Arrowhead Pharmaceuticals reported fiscal 2026 full-year revenue of $450.8M, down 45.6% from…
The revenue decline was expected as fiscal 2025 included large upfront payments from licensing deals. Focus shifts to REDEMPLO commercial ramp and the sHTG sNDA review under the STAR program, with a…
- NEUTRAL SC 13G/ANov 5, 2026
FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 9,307,349…
FMR LLC's passive stake update shows no material change in position or intent. Monitor next 13F filing for any shift in Fidelity's aggregate ARWR holdings.
- BULLISH 8-KNov 4, 2026
Arrowhead Pharmaceuticals refinanced its existing $400M senior secured term loan with Sixth…
The refinancing removes the onerous MOIC prepayment penalty and revenue sweeps that capped Arrowhead's strategic flexibility. With lower cash interest and no amortization, the company has greater…
- BEARISH INST-CLUSTERNov 2, 2026
Three institutional sellers reduced ARWR holdings by $34.3M in Q3 2026, while one small buyer…
The cluster shows concentrated selling by two active asset managers (Principal Financial and Assenagon) who collectively exited $34.1M in ARWR. With no insider buying and a 45-day reporting lag…
All ARWR filing & press-release reports (7)
- 8-K reportNov 12, 2026
- SC 13G/A reportNov 5, 2026
- 8-K reportNov 4, 2026
- INST-CLUSTER reportNov 2, 2026
- INST-CLUSTER reportSep 10, 2026
- CLUSTER reportAug 20, 2026
- 8-K reportJun 16, 2026